Aleva Neurotherapeutics Scores CE Mark For Deep Brain Stimulation System
Aleva Neurotherapeutics is taking its directSTIM deep brain stimulation system to the European market following receipt of CE mark. With a fresh round of financing under its belt, Aleva has its eyes on the US next.
You may also be interested in...
Aleva Neurotherapeutics has made two senior management appointments as it prepares to take its first deep brain stimulation product to CE mark approval and to market.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.